Daily Ards Research Analysis
Three papers stand out today: a mechanistic study showing that myeloid mTOR signaling can be therapeutically targeted with a nanobiologic to prevent infection-associated hyperinflammation; a human precision-cut lung slice model demonstrating heme-driven injury that recapitulates ARDS-like inflammatory and matrix signatures; and a preclinical study introducing a solid hydrogen carrier (coral calcium hydride) that improves ARDS-like injury via Trx2/Myo19/Drp1–mediated mitochondrial quality control
Summary
Three papers stand out today: a mechanistic study showing that myeloid mTOR signaling can be therapeutically targeted with a nanobiologic to prevent infection-associated hyperinflammation; a human precision-cut lung slice model demonstrating heme-driven injury that recapitulates ARDS-like inflammatory and matrix signatures; and a preclinical study introducing a solid hydrogen carrier (coral calcium hydride) that improves ARDS-like injury via Trx2/Myo19/Drp1–mediated mitochondrial quality control.
Research Themes
- Immunometabolic targeting of myeloid cells in infection-associated hyperinflammation
- Human ex vivo models elucidating ARDS pathophysiology
- Mitochondrial quality control and hydrogen-based therapeutics in ARDS
Selected Articles
1. Targeting mTOR in myeloid cells prevents infection-associated inflammation.
Single-cell transcriptomics in COVID-19 identified myeloid mTOR signaling as a key regulator of hyperinflammation. A myeloid-targeted mTOR-inhibiting nanobiologic efficiently homes to myeloid cells and progenitors, and targeting this pathway prevents infection-associated inflammation.
Impact: Introduces a precision immunometabolic strategy—myeloid-targeted mTOR inhibition—with broad applicability across infection-induced hyperinflammation, potentially relevant to ARDS and sepsis.
Clinical Implications: Suggests a therapeutic avenue to modulate dysregulated innate immunity in infection-associated ARDS by targeting myeloid mTOR; supports development of trials evaluating safety, timing, and dosing of myeloid-directed mTOR inhibition.
Key Findings
- Single-cell RNA-seq of circulating immune cells in COVID-19 patients implicates myeloid mTOR signaling as a critical regulator of hyperinflammation.
- An mTOR-inhibiting nanobiologic efficiently targets myeloid cells and their progenitors in the bone marrow.
- Targeting mTOR in myeloid cells prevents infection-associated inflammation (as per study title), indicating a tractable therapeutic pathway.
Methodological Strengths
- Use of single-cell transcriptomics in human COVID-19 to pinpoint pathway-level dysregulation.
- Development and deployment of a myeloid-targeted nanobiologic enabling cell-specific mTOR inhibition.
Limitations
- Abstract does not detail clinical outcomes; translational efficacy in ARDS patients remains to be established.
- Preclinical stage with safety, dosing, and durability yet to be evaluated in humans.
Future Directions: Test myeloid-targeted mTOR inhibition across sepsis/ARDS models; define therapeutic window, biomarkers of response, and safety in early-phase clinical trials.
Infections, cancer, and trauma can cause life-threatening hyperinflammation. In the present study, using single-cell RNA sequencing of circulating immune cells, we found that the mammalian target of rapamycin (mTOR) pathway plays a critical role in myeloid cell regulation in COVID-19 patients. Previously, we developed an mTOR-inhibiting nanobiologic (mTORi-nanobiologic) that efficiently targets myeloid cells and their progenitors in the bone marrow.
2. Heme-induced lung injury in human precision cut lung slices: a new model for acute lung injury.
Circulating heme is elevated in COVID-19 ARDS and induces dose-dependent cell death, inflammatory cytokine release, and ECM remodeling in human precision-cut lung slices. The heme-stimulated PCLS model reproduces inflammatory signatures seen in patient blood, providing a human-relevant ex vivo platform for ARDS research.
Impact: Introduces a human tissue-based ex vivo model linking circulating heme to ARDS-like injury, addressing a key bottleneck in translational ARDS research.
Clinical Implications: Supports investigation of heme-scavenging and heme metabolism-modulating strategies (e.g., hemopexin, HO-1 pathways) as potential interventions in ARDS.
Key Findings
- Serum heme and HO-1 levels are elevated in patients with COVID-19 and ARDS versus controls.
- Heme induces dose-dependent cell death, proinflammatory signaling, and extracellular matrix changes in human PCLS.
- Integrative omics identified 27 shared markers (adj p<0.05), aligning with inflammatory cytokines elevated in patient blood; LPS did not augment heme cytotoxicity.
Methodological Strengths
- Human precision-cut lung slice model with direct translational relevance.
- Multi-omic profiling (transcriptome and proteome) and patient–tissue concordance.
Limitations
- Ex vivo model lacks systemic immune-vascular interactions and mechanical forces.
- Sample size and etiologic generalizability beyond COVID-19 ARDS are not detailed.
Future Directions: Evaluate heme-scavenging interventions in PCLS and in vivo; test across diverse ARDS etiologies and integrate with biomechanical injury models.
BACKGROUND: Acute respiratory distress syndrome (ARDS) causes high mortality and has no specific pharmacological treatment. Scarcity of drugs against ARDS is in part due to the lack of models for ARDS. As raised serum heme levels are associated with higher mortality in patients with ARDS, we hypothesised that circulating heme contributes to ARDS pathology and can induce lung injury resembling human disease. We aimed to develop a new model for acute lung injury and ARDS research with heme-induced injury in human precision cut lung slices (PCLS). METHODS: We analysed heme and its degrading enzymes along with inflammatory cytokines in patients with coronavirus disease 2019 (COVID-19) and ARDS compared to healthy adult subjects. In PCLS, we studied effects of heme on cell survival, membrane integrity, the transcriptome by gene expression and the proteome by protein expression analysis or ELISA. We also tested synergistical effects with lipopolysaccharide (LPS) on cell survival in addition to heme to simulate bacterial infection. RESULTS: Patients with COVID-19 and ARDS had increased serum levels of heme and heme oxygenase 1 (HO-1) compared to controls. In PCLS, heme induced cell death in a dose-dependent manner, stimulated pro-inflammatory and injury signals and triggered changes to the extracellular matrix (ECM). Comparative analyses of the lung transcriptomic and proteomic signatures revealed 27 common markers (log2 fold change greater than 1, at adjusted (adj) p-value < 0.05 significant), most of which were inflammatory. Similar inflammatory cytokines were raised in blood from patients with COVID-19 and ARDS compared to controls. LPS did not increase cytotoxicity in addition to heme. CONCLUSION: Heme induced inflammatory cytokine release and cell death in human PCLS, resembling the patterns observed in blood samples from patients with COVID-19 and ARDS. Thus, heme-stimulated PCLS represent a novel ex vivo model for mechanistic studies for acute lung injury and ARDS.
3. Coral calcium hydride promotes peripheral mitochondrial division and reduces AT-II cells damage in ARDS via activation of the Trx2/Myo19/Drp1 pathway.
In LPS-induced ARDS mice, coral calcium hydride (CCH) improved survival comparably to hydrogen gas, reduced lung hemorrhage and edema, and enhanced pulmonary function and microcirculation. Mechanistically, CCH activated Trx2 and the Myo19/Drp1 axis to promote peripheral mitochondrial division in AT-II cells, mitigating oxidative stress and mitochondrial dysfunction.
Impact: Proposes a practical, potentially safer hydrogen delivery strategy with defined mitochondrial mechanisms that could be translated to ARDS therapy.
Clinical Implications: Solid hydrogen carriers like CCH may circumvent safety issues of gas inhalation and offer a mitochondria-targeted adjunct for ARDS; requires dosing, safety, and multi-etiology validation.
Key Findings
- CCH improved survival in LPS-induced ARDS mice to a degree comparable with hydrogen inhalation and outperformed untreated controls.
- CCH reduced pulmonary hemorrhage and edema and improved pulmonary function and local microcirculation.
- CCH activated Trx2/Myo19/Drp1 signaling, promoting peripheral mitochondrial division in AT-II cells and reducing oxidative stress and mitochondrial dysfunction.
Methodological Strengths
- Direct head-to-head comparison with hydrogen inhalation alongside survival and physiological endpoints.
- Mechanistic dissection implicating Trx2/Myo19/Drp1 in mitochondrial quality control.
Limitations
- Single-etiology (LPS) mouse model; human safety, pharmacokinetics, and dosing remain unknown.
- Long-term outcomes and off-target effects of CCH were not addressed.
Future Directions: Assess pharmacokinetics, safety, and dosing of CCH; validate across multiple ARDS models and large animals; explore combination with lung-protective ventilation.
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treatment measures. Our previous study confirmed that inhalation of hydrogen gas can reduce the acute lung injury of ARDS, but the application of hydrogen has flammable and explosive safety concerns. Drinking hydrogen-rich liquid or inhaling hydrogen gas has been shown to play an important role in scavenging reactive oxygen species and maintaining mitochondrial quality control balance, thus improving ARDS in patients and animal models. Coral calcium hydrogenation (CCH) is a new solid molecular hydrogen carrier prepared from coral calcium (CC). Whether and how CCH affects acute lung injury in ARDS remains unstudied. In this study, we observed the therapeutic effect of CCH on lipopolysaccharide (LPS) induced acute lung injury in ARDS mice. The survival rate of mice treated with CCH and hydrogen inhalation was found to be comparable, demonstrating a significant improvement compared to the untreated ARDS model group. CCH treatment significantly reduced pulmonary hemorrhage and edema, and improved pulmonary function and local microcirculation in ARDS mice. CCH promoted mitochondrial peripheral division in the early course of ARDS by activating mitochondrial thioredoxin 2 (Trx2), improved lung mitochondrial dysfunction induced by LPS, and reduced oxidative stress damage. The results indicate that CCH is a highly efficient hydrogen-rich agent that can attenuate acute lung injury of ARDS by improving the mitochondrial function through Trx2 activation.